Dr Sarah Cant, Policy Manager at Breakthrough Breast Cancer, says: "This research, whilst interesting, is only relevant to a very small proportion of women - those with a strong family history but without a BRCA gene fault. The researchers suggest that these women could benefit from extra breast screening and taking tamoxifen to reduce their breast cancer risk. However, tamoxifen is not currently licensed for this use in the UK.
More...
Threaded Mode